Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karin Briner is active.

Publication


Featured researches published by Karin Briner.


Tetrahedron Letters | 2001

Synthesis of constrained arylpiperidines using intramolecular Heck or radical reactions

Christophe Morice; Mathias Domostoj; Karin Briner; André Mann; Jean Suffert; Camille-Georges Wermuth

Two intramolecular routes were experimented to reach the hexahydrobenzofuro(2,3-c)pyridine platform: a Heck and a radical reaction. The radical route was applicable to all substrates, whereas the Heck route was of limited use. The key adducts were obtained via a Mitsunobu condensation between halogenated phenols and an allylic alcohol, the 3-hydroxy-tetra- hydropyridine.


Frontiers in Psychiatry | 2017

Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder

Michelle M. Rodriguez; Carl D. Overshiner; J. David Leander; Xia Li; Denise Morrow; Richard G Conway; David L. Nelson; Karin Briner; Jeffrey M. Witkin

Selective serotonin reuptake inhibitors (SSRIs) are the only effective pharmacological treatments for obsessive–compulsive disorder (OCD). Nonetheless, their generally limited efficacy, side-effects, and delayed onset of action require improved medications for this highly prevalent disorder. Preclinical and clinical findings have suggested serotonin2C (5-HT2C) receptors as a potential drug target. Data in rats and mice are presented here on the effects of a novel 5-HT2C receptor agonist ((3S)-3-Methyl-1-[4-(trifluoromethyl)-7-benzofuranyl]-piperazine) (CPD 1) with high potency and full efficacy at 5-HT2C receptors and less potency and partial agonism at 5-HT2A and 5-HT2B receptors. Effects of CPD 1 on consummatory (schedule-induced polydipsia in rats) and non-consummatory behaviors (marble-burying and nestlet-shredding in mice) that are repetitive and non-habituating were studied. We also evaluated the effects of CPD 1 in rats with isoproterenol- and deprivation-induced drinking in rats to compare with the polydipsia studies. The SSRIs, fluoxetine, and chlomipramine decreased the high rates of drinking in rats engendered by a schedule of intermittent food delivery (schedule-induced polydipsia). The effects of fluoxetine, but not of d-amphetamine, were prevented by the selective 5-HT2C receptor antagonist SB242084. The 5-HT2C receptor agonists Ro 60-0175 and CPD 1 also decreased drinking, but unlike the SSRIs and Ro 60-0175, CPD 1 dose-dependently decreased excessive drinking without affecting lever press responses that produced food. The effects of CPD 1 were prevented by SB242084. CPD 1 also suppressed drinking induced by isoproterenol and by water deprivation without affecting normative drinking behavior. CPD 1, like fluoxetine, also suppressed marble-burying and nestlet-shredding in mice at doses that did not affect rotarod performance or locomotor activity. The behavioral specificity of effects of CPD 1 against repetitive and excessive behaviors suggests a potential therapeutic application in OCD.


Archive | 2000

Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists

Karin Briner; Joseph Paul Burkhart; Timothy Paul Burkholder; Brian Eugene Cunningham; Matthew Joseph Fisher; William Harlan Gritton; Shawn Christopher Miller; Jeffrey Thomas Mullaney; Matthew Robert Reinhard; Dennis Charles Thompson; Leonard L. Winneroski; Yanping Xu


Archive | 2002

Piperazine- and piperidine-derivatives as melanocortin receptor agonists

Karin Briner; Christopher William Doecke; Vincent Mancuso; Michael John Martinelli; Timothy I. Richardson; Roger Ryan Rothhaar; Qing Shi; Chaoyu Xie


Archive | 2002

Substituted piperidines/piperazines as melanocortin receptor agonists

Ryan T. Backer; Karin Briner; Christopher William Doecke; Matthew Joseph Fisher; Steven L. Kuklish; Vincent Mancuso; Michael J. Martinelli; Jeffrey Thomas Mullaney; Chaoyu Xie


Journal of Medicinal Chemistry | 2004

Synthesis and Structure-Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor

Timothy I. Richardson; Paul L. Ornstein; Karin Briner; Matthew Joseph Fisher; Ryan T. Backer; C. Kelly Biggers; Michael P. Clay; Paul J. Emmerson; Larry Wayne Hertel; Hansen M. Hsiung; Saba Husain; Steven D. Kahl; Jonathan A. Lee; Terry D. Lindstrom; Michael J. Martinelli; John P. Mayer; Jeffery T. Mullaney; Thomas P. O'brien; Joseph Matthew Pawlak; Kevin D. Revell; Jikesh Shah; John M. Zgombick; R. Jason Herr; Alex Melekhov; Peter B. Sampson; Chi-Hsin R. King


Archive | 2006

6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists

John Gordon Allen; Karin Briner; Anne Marie Camp; Manuel Javier Cases-Thomas; Richard Charles Hoying; Maria Angeles Martinez-Grau; Michael Philip Mazanetz; Natalia Pokrovskaia; Richard Edmund Rathmell; Roger Ryan Rothhaar; Selma Sapmaz; Andrew Caerwyn Williams


Archive | 2000

Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists

Karin Briner; Joseph Paul Burkhart; Timothy Paul Burkholder; Matthew Joseph Fisher; William Harlan Gritton; Daniel Timothy Kohlman; Sidney Xi Liang; Shawn Christopher Miller; Jeffrey Thomas Mullaney; Yao-Chang Xu; Yanping Xu


Bioorganic & Medicinal Chemistry Letters | 2005

Privileged structure-based ligands for melanocortin receptors—tetrahydroquinolines, indoles, and aminotetralines

Matthew Joseph Fisher; Ryan T. Backer; Saba Husain; Hansen M. Hsiung; Jeffrey Thomas Mullaney; Thomas P. O’Brian; Paul L. Ornstein; Roger Ryan Rothhaar; John M. Zgombick; Karin Briner


Bioorganic & Medicinal Chemistry Letters | 2006

Synthesis and structure-activity relationships of novel dipeptides and reduced dipeptides as ligands for melanocortin subtype-4 receptor

Qing Shi; Paul L. Ornstein; Karin Briner; Timothy I. Richardson; Macklin Brian Arnold; Ryan T. Backer; Jennifer L. Buckmaster; Emily J. Canada; Christopher W. Doecke; Larry Wayne Hertel; Nick Honigschmidt; Hansen M. Hsiung; Saba Husain; Steve L. Kuklish; Michael J. Martinelli; Jeffrey Thomas Mullaney; Thomas P. O’Brien; Matt R. Reinhard; Roger Ryan Rothhaar; Jikesh Shah; Zhipei Wu; Chaoyu Xie; John M. Zgombick; Matthew Joseph Fisher

Collaboration


Dive into the Karin Briner's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Qing Shi

Eli Lilly and Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge